Orion Group's Financial Statement documents for 2019 have been published. The documents are available in Finnish and English on the Company's website at http://www.orion.fi/en.
The official Financial Statement documents, which include the Financial Statements, the Report by the Board of Directors and the Auditor's Report are available in Finnish at http://www.orion.fi/yhtiokokous2020.
Orion's Corporate Governance Statement for year 2019, adopted by the Board of Directors, is published as a separate report in Finnish and English on the Company's website at http://www.orion.fi/en.
SVP, Corporate Functions
Tuukka Hirvonen, Investor Relations, tel. +358 010 426 2721
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.